Overview

Gender

male

Devin Wiley (PhD Chemical Engineering, 2013, Caltech; MD, 2015, Keck SOM) is a Co-founder, Chief Medical Officer, and Head of Research and Development at Circumvent Pharmaceuticals.Wiley helped lead a Caltech-based team in winning the NIH 2015 Neurostartup Challenge that provided seed funding for Circumvent, and he secured additional funding through a 2017 NIH SBIR grant award. At Circumvent, Wiley manages the discovery, preclinical, and clinical development programs for small molecule Enzyme Replacement Therapies (smERTs) that cross the blood-brain barrier, have minimal toxicity profiles, and that retain activity in treating the ultra-rare and uniformly fatal neurodegenerative disease, Neuronal Ceroid Lipofuscinosis-1 (CLN1 Batten Disease), for which there is currently no therapeutic option. He is charting a path for the development of hydroxylamine-derived smERTs as a new class of therapeutic, with a mission of creating a treatment landscape for CLN1 Batten Disease patients that both extends their lifespan and improves their quality of life.